Optibiotix Health Share Discussion Threads

[michaelmouse] 12/1/2017 13:42

And next up on today's losers board is Orogen Gold. No please don't it's getting ridiculous. Oh no it's true. You guessed it.



Tipped as a buy at 0.33p with price target of 0.6p. Oops again. Currently 0.0115p. Never quite reached 0.6p did it?

A mere 97% loss.

If Carlsberg did the worst tipsters ever..............

[riskybusiness1] 12/1/2017 11:59

Info on new specialist pr company:'Vane Percy & Roberts is a professional communications consultancy with national and international clients. The business is led by two directors, Simon Vane Percy and Sarah Roberts who play a hands-on role in all accounts. Our approach gives all clients - regardless of their size - access to the senior team members which is relatively unique in PR and makes us stand out from the crowd.Simon has worked in PR for over 30 years and his experience spans some of the world's largest blue-chips including BA, Apple, IBM, Siemens. In the past 15 years he has concentrated on the healthcare sector providing consultancy to nearly all major companies in this space.Having worked in PR for over 20 years Sarah has managed a range of global and UK based communications projects. She has experience in providing high level consultancy to a to a range of clients in both the public and private sectors including Pfizer, Merck, Schering-Plough and the NHS'Seems like exactly the type of people opti need on board during the year opti starts launching its next generation products

[jimbobjames2002] 12/1/2017 11:44

Here's a link to the programme for the ProBiotia event.



2 OPTI talks on page 5:

Development of a synergistic synbiotic for Lactobacillus plantarum LP-LDL
targeting cholesterol reduction
Dr Sofia Kolida, OptiBiotix Health

An assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum
LP-LDL in adults with normal to mildly elevated cholesterol
Stephen OHara, OptiBiotix Health

[deeppockets] 12/1/2017 11:40

Could we finally about to break the downtrend? What are technical upside targets if we do?

[neftanikoff] 12/1/2017 11:34

re 832 another question for him to NOT answer,

[diamond fibre] 12/1/2017 11:22

Stephen said the shares were worth 2 pounds two years ago what would he sell for now?

[john henry] 12/1/2017 11:18

Imho stock is starting to get a little tighter I just added at 2x5ks and the offer went from 64.98p to 65.5p. Must have been the 25k 64.5p buy being worked.

[nicktopten] 12/1/2017 11:14

a three fold increase in the strains ability to lower cholesterol would easily put the product on a par with statins, if not better?

[judijudi] 12/1/2017 11:13

What do you mean bobdown?

[bobdown2] 12/1/2017 11:11

Realisation is starting to kick in.

[john henry] 12/1/2017 10:56

The second abstract will be presented as a poster and covers the work on species specific microbiome modulators which the Company has used to enhance the cholesterol reducing effect of their cholesterol reducing strain (LP-LDL(R)). In the case of this strain, it leads to a threefold increase in the strains ability to lower cholesterol.Potentially absolutely massive.Markets fast asleep at the moment.

[spike_1] 12/1/2017 10:50

bobdown - exactly right IMO.

[owenmo] 12/1/2017 10:43

Or, Spike, that the market is asleep. I can't agree with your other hypotheses, and, agreed, the market isn't customarily asleep - hence, as I uttered (twice!); it's beyond me - that's thrice.

[someuwin] 12/1/2017 10:43

Why would you expect a big share price response the this news?

It was released as an RNSNON which means it is not considered to be price moving information.

Nevertheless, it is good to know and the share price should rise as the presentation (and further details of the cardiovascular products) nears.

[bobdown2] 12/1/2017 10:42

It's a great r.n.s hidden behind the notice of a conference. am I mistaken or does it virtually tell us that as well as gofigure some of the other products work and are ready for the market place. Still I got mine today for a good price.

[spike_1] 12/1/2017 10:37

Acceptance for presentation at the conference acts as a benchmark towards peer acceptance, but only up to a point. However, the data released there - if actually important - will translate into appropriate peer reviewed publications publishing articles, and we have been lead to believe that will happen. (For instance publication in 'Nature' is considered very important for certain science as to get published the research/results need to be innovative / pioneering, and considered 'scientifically viable'. There then follows further peer review by fellow scientists and commercial deals if appropriate).

Certainly from Opti's point of view it allows products to then come onto the market that have a scientific differentiator from other products, and in Opti's case should lead to the holy grail of acceptance as prescription medicine (a long route).

Having said a long route, I don't believe that is quite the same case for products applied externally (Skinbiotix), which I recollect have a somewhat shorter route.

The lack of market response so far suggests that either the news is not as important as Opti makes out (quite possible), OR SOH has cried wolf one to many times.

Anyway I bought a few this morning.

Best wishes Mike

[owenmo] 12/1/2017 10:36

This, to my eye, is one bullish RNS; yes if we knew where it leads, the share price would respond in kind; as to why, however, there is no reaction whatever, is beyond me. just beyond me.

[bobdown2] 12/1/2017 10:28

The bit that stands out....will support the launch of a range of products to reduce L.D.L cholesterol, blood pressure and cardiovascular risk, planned for the spring of 2017. at least Three product luanches in the not to distant future and go figure gaining momentum. It certainly does look good.

[judijudi] 12/1/2017 10:14

Bring on the RNS's that really matter and really will make a difference

[bobdown2] 12/1/2017 09:59

The conference is world renowned as a key meeting place for a community of scientists and business leaders who want to translate science into new products in the growing supplements and ingredients markets.. This looks like the conference to be at and might there be an r.n.s statement about cholesterol on the morning of the conference.

[elrico] 12/1/2017 09:48

Some people will view this morning RNs as PR spin and why wouldn't they, they don't understand OPTI, its stated strategy or the industry, they way it works, etc. It is easy to dismiss the Berlin event as just a bunch of scientists having a jolly, but it is a key event and one that helps shape the future in the pre & probiotics.

Another key factor in the RNs was "planned" so the plan is new product launch this spring, it is no longer "anticipated."

OPTI is a leader in its field, there will be plenty of corporate following.

[owenmo] 12/1/2017 09:47

A question I ask myself, and with no apparent answer: If neither the principles in these new stockbroking and PR firms (not to mention their many clients), no more than the newly engaged in-house Executives, aren't piling headlong into this story (shareholding-wise) that exercises the rest of us so enthusiastically, why would I have done? And yet another conundrum: which would I prefer to discover as a priority - that Michaelmouse or the persistent seller would have capitulated?

[1bokke] 12/1/2017 09:25

Still haven't answered my question then?